

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HANGZHOU TIGERMED CONSULTING CO., LTD.**

### **杭州泰格醫藥科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3347)**

## **CHANGE OF PAYMENT DATE OF FINAL DIVIDEND OF H SHARES**

Reference is made to the poll voting results announcement of the annual general meeting of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) dated May 23, 2023 (the “**Announcement**”) in relation to, inter alia, payment of the final dividend for the year ended December 31, 2022 in respect of the H Shares.

The Company hereby announces that the payment date of the final dividend for the year 2022 declared in respect of the H Shares will be changed to July 7, 2023.

Save as disclosed above, all other information and content contained in the Announcement remain unchanged.

An announcement regarding the details of the distribution of the final dividend of A Shares will be published on the website of the Shenzhen Stock Exchange (<http://www.szse.cn>) for information of Shareholders of A Shares.

By order of the Board  
**Hangzhou Tigermed Consulting Co., Ltd.**  
**Ye Xiaoping**  
Chairman

Hong Kong, June 26, 2023

*As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors are Dr. Yang Bo, Mr. Liu Kai Yu Kenneth and Mr. Yuan Huagang.*